ISRCTN19040577已完成4 期
A prospective single-centre single-arm open-label study of the long-term use of a LHRH agonist (Decapeptyl SR 11.25mg) in combination with livial add-back therapy in the management of chronic cyclical pelvic pain in pre-menopausal women
Sheffield Teaching Hospitals NHS Trust (UK)0 个研究点目标入组 31 人开始时间: 2010年4月29日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 31
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Female
入选标准
- •Patients must satisfy all of the following entry criteria before they will be allowed to participate in the study:
- •1. The patient must have given written (personally signed and dated) informed consent given before completing any study-related procedure, which means any assessment or evaluation that would not have formed part of their normal medical care
- •2. The patient must be aged between 18 and 45 years inclusive, female only
- •3. The patient must have a clinical diagnosis of CCPP of at least 6 months duration (with or without evidence of endometriosis)
- •4. The patient must have had a laparoscopy within three years prior to the Screening visit
- •5. The patient must have had regular menstrual cycles (between 24 and 42 days) for the 3 months prior to screening
- •6. Treatment with a LHRHa is indicated for the patient
- •7. The patient must be able to understand, and willing to comply with the requirements of the protocol
排除标准
- •Patients who satisfy any of the following criteria must not be included in the study:
- •1. The patient has been treated with any LHRHa within 6 months prior to screening
- •2. The patient has been treated with Danazol, gestrinone or cyproterone acetate within the 6 months prior to screening or anticipated requirement during the study
- •3. The patient has used cyclical progestogens or combined oral contraceptives within one full menstrual cycle (including a spontaneous bleed) prior to screening, or anticipated requirement for these treatments during the study period
- •4. The patient is treated with any other medication for CCPP (other than simple analgesics) within three months prior to screening
- •5. The patient has continuous or acyclic pelvic pain
- •6. The patient has known metabolic bone disease
- •7. The patient has an abnormal full blood count or liver or renal function at screening or within the 6 months prior to screening
- •8. The patient has unexplained vaginal bleeding
- •9. The patient has a bone mineral density age adjusted T-Score of -2 or below at the screening visit
- •10. The patient has any other medical condition or abnormality that in the opinion of the investigator would impact upon the safety or efficacy of the study treatment or any study assessments
- •11. The patient is receiving concomitant treatment with coumarin or indanedione derivatives
- •12. The patient has a known contraindication, allergy or hypersensitivity to any of the test compounds or materials (including both Decapeptyl SR and Livial)
- •13. The patient is pregnant or lactating. Female patients of child-bearing potential (i.e. who are not surgically sterile) must have a negative urine pregnancy test at the baseline visit.
- •14. The patient is planning a pregnancy within 31 months of screening
- •15. The patient is of child-bearing potential and is unwilling to use adequate barrier contraception for the duration of the study
- •16. The patient has received any investigational drug therapy within 30 days prior to the study, or is scheduled to receive such a drug during the study period
- •17. The patient has previously entered this study
研究者
相似试验
已完成
不适用
Algorithm optimization of a new continuous glucose monitoring system in children, adolescents and adult patients with type 1 diabetes – A pilot study.Type 1 diabetesACTRN12621000836831i-SENS, Inc.30
已完成
4 期
The primary purpose of this study is to evaluate the post-marketingsafety of ImbruvicaTM (ibrutinib capsule 140 milligram [mg]) underactual conditions of use, and to understand the incidence ofadverse events (AEs) (serious and non-serious AEs).CTRI/2019/04/018710Johnson and Johnson Private Limited75
招募中
Unknown
A prospective study to evaluate the safety and the efficacy of blood pressure reduction of Laparoscopic RDN in patients with resistant hypertensioDiseases of the circulatory systemKCT0009209DeepQure10
已完成
1 期
A clinical trial to study the safety and efficacy of ReliNethra C-Au (Autologous Conjunctival epithelial cell graft) in patients with pterygiumCTRI/2009/091/000641Reliance Life Sciences Pvt Ltd25
招募中
不适用
Safely Discontinue Antiviral Treatment in Patients With Chronic Hepatitis B (ADAPT)KCT0005929Asan Medical Center140